Income statement, balance sheet and cash flow statement for the last 5 fiscal years, taken from the XBRL data Coya Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2022
FY2022
FY2023
FY2024
FY2025
Revenue
0
6
3.55
7.95
Research and development
2.54
4.41
5.5
11.9
16.7
General and administrative
2.31
4.85
7.83
8.89
11.4
Operating expenses
4.87
9.81
13.9
20.8
30.5
Operating income
-4.87
-9.81
-7.9
-17.2
-22.6
Other non-operating income
-0.02
0.06
0.64
1.65
1.33
Pre-tax income
-12.2
-7.26
-15.6
-21.2
Income tax
0
0.72
-0.72
0
Net income
-4.89
-12.2
-7.99
-14.9
-21.2
EBITDA
-4.85
-9.78
-7.88
-17.2
-22.5
EPS, basic
-1.89
-4.73
-0.79
-0.98
-1.27
EPS, diluted
-1.89
-4.73
-0.79
-0.98
-1.27
Shares, basic (weighted)
2.59
2.59
10.2
15.2
16.7
Shares, diluted (weighted)
2.59
2.59
10.2
15.2
16.7
Balance sheet
FY2022
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
4.34
5.93
32.6
38.3
46.8
Other current assets
0.24
1.25
1.07
5.97
3.12
Total current assets
4.58
7.18
41.2
44.3
49.9
Property, plant and equipment
0.12
0.09
0.07
0.04
0.01
Total assets
4.79
8.4
41.3
44.3
50
Accounts payable
0.86
1.82
1.16
1.59
1.06
Accrued liabilities
0.29
2.01
2.97
1.39
3.61
Deferred revenue
0.92
0.85
1.2
Total current liabilities
1.15
3.82
5.05
3.82
5.87
Total liabilities
1.15
16.8
5.63
4.77
6.92
Paid-in capital
0.47
0.68
61.5
80.3
105
Retained earnings
-5.62
-17.9
-25.9
-40.7
-62
Shareholders' equity
3.64
-8.39
35.6
39.6
43
Total equity
3.64
-8.39
35.6
39.6
43
Total liabilities and equity
4.79
8.4
41.3
44.3
50
Shares outstanding
2.59
2.59
14.4
16.7
20.9
Cash flow statement
FY2022
FY2022
FY2023
FY2024
FY2025
Net income
-4.89
-12.2
-7.99
-14.9
-21.2
Depreciation and amortization
0.02
0.03
0.03
0.03
0.03
Stock-based compensation
0.23
0.21
0.87
2.66
4.29
Change in payables
0.67
0.85
0.3
0.48
-0.53
Cash from operations
-3.9
-7.24
-11.2
-10.3
-10.7
Cash from investing
-0.14
-0.53
-0.54
-0.03
-1.16
Stock issued
0
0
0.09
14
20.3
Cash from financing
-0.34
9.36
38.4
16
20.4
Net change in cash
-4.38
1.59
26.7
5.71
8.48
Income taxes paid
0.73
-0.73
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $5.08 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-288.7%
Operating income / revenue.
EBITDA margin
-288.5%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-270.2%
Net income / revenue.
Operating cash flow margin
-196.1%
Cash from operations / revenue.
Return on equity (ROE)
-50.1%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-45.8%
Net income / average total assets.
Return on invested capital (ROIC)
-19,250.0%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
211.8%
Research and development expense / revenue.
Stock-based pay / revenue
66.3%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
0.2%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
123.6%
Revenue vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
8.7%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
12.6%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
81.2%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
9.8%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
86.2%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
13.4x
Current assets / current liabilities.
Quick ratio
12.3x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
12.3x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.34
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.67
Cash from operations / diluted weighted shares.
Book value per share
$1.84
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
14.9x
Market cap / revenue.
P/B
2.75x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
2.75x
Market cap / tangible book value, when positive.
EV/Sales
9.48x
Enterprise value / revenue.
Earnings yield
-18.2%
Net income / market cap (the inverse of P/E).
What was Coya Therapeutics, Inc.'s revenue in fiscal 2025?
Coya Therapeutics, Inc. reported revenue of $7.9M for fiscal 2025, 123.6% higher than the year before.
Was Coya Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $21.2M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.